Diana Sutherland, NP, a nurse practitioner at the University of Cincinnati, discusses the promise of CDK4 inhibitors in patients with metastatic breast cancer.

CDK4 inhibitors are an exciting option for patients with metastatic disease, due to their portability and convenience, according to Sutherland. If the adverse effects associated with treatment can be properly managed, patients can remain on treatment for several years and do very well while maintaining a positive quality of life, she says.

Moreover, the field remains excited to observe how this class of drug performs within the frontline setting, as well, Sutherland concludes.

Videos

Diana Sutherland, NP, discusses the promise of CDK4 inhibitors in patients with metastatic breast cancer.

Diana Sutherland, NP

Articles

Sutherland on the Promise of CDK4 Inhibitors in Metastatic Breast Cancer